| Author(s)/Faculty: Allan Gibofsky, MD, JD, MACR, FACP, FCLM ; Jonathan Kay, MD | |
| Release Date: 8/29/2016 | Expiration Date: 8/28/2017 |
| Credit Type: CME | Number of Credits: 0.25 |
| Content Type: Video | Provider: |
| Drs. Gibofsky and Kay examine the immunopathogenesis and therapeutic landscape of RA and allied conditions as well as strategies to mitigate risk from biologic and immune-based agents. | |
CME Information
Support Statement: This activity is supported by educational grants from Bristol-Myers Squibb, Lilly, and Pfizer.
Target Audience: The intended audience for this activity is rheumatologists, rheumatology nurses, and other health care professionals involved in the treatment of patients with rheumatoid arthritis (RA).
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as strategies to mitigate risk from biologic and immune-based agents.
Activity Chair:
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director of the R.J. Fasenmyer Center for Clinical Immunology
Cleveland Clinic
Cleveland, OH
Faculty:
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY
Jonathan Kay, MD
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Professor of Medicine
University of Massachusetts Medical School
University of Massachusetts Memorial Medical Center
Worcester, MA
Reviewers:
Kevin D. Deane, MD, PhD
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
This enduring material is approved for 1 year from the date of original release, August 29, 2016 to August 28, 2017.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Steering Committee and Faculty report the following relationship(s):
Leonard H. Calabrese, DO
Consulting Fee: GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Janssen
Joseph E. Craft, MD
Non-CME Services Fees: Bristol-Myers Squibb, MedImmune
John J. Cush, MD
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB
Clinical Investigator: AbbVie, AstraZeneca, Celgene, Janssen, Novartis, Pfizer
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Consulting Fee: AbbVie, Celgene, Iroko Pharmaceuticals, Pfizer, Takeda
Speakers Bureau: AbbVie, Celgene, Iroko Pharmaceuticals, Pfizer
Ownership Interest: AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Regeneron
Jonathan Kay, MD
Consulting Fee: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim GMbH, Bristol-Myers Squibb, Elil-Lilly, Epirus Biopharmaceuticals, Genentech Inc., GlaxoSmithKline, Hospira, Janssen, Merck, Myriad, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, UCB
Contract Research: (Paid to Institution) AbbVie, Genentech, Eli-Lilly, Pfizer, Roche
Elizabeth Kirchner, CNP, MSN
Consulting Fee: Pfizer, Sanofi
Speakers Bureau: Crescendo Bioscience
William F.C. Rigby, MD
Consulting Fee: Bristol-Myers Squibb, Lilly, Pfizer, Roche
Non-CME Services Fees: Bristol-Myers Squibb
Contracted Research: Amgen, Bristol-Myers Squibb, Pfizer, Roche
Sergio Schwartzman, MD
Consulting Fee: AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron
Speakers Bureau: AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer
Ownership Interest: Amgen, Gilead, Medtronic, Pfizer
Board Member: Discus-Analytics National Psoriasis Foundation Scientific Advisory Board Member: Bioscience, Crescendo
Gregg Silverman, MD
Consulting Fee: Bristol-Myers Squibb, Genentech
Speakers Bureau: Genentech
Reviewers report the following relationship(s):
Kevin Deane, MD
Consulting Fee: Janssen
Honoraria: Medscape
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.